CA2225255A1 - Combinaisons d'inhibiteurs de farnesyl-proteine transferase - Google Patents

Combinaisons d'inhibiteurs de farnesyl-proteine transferase Download PDF

Info

Publication number
CA2225255A1
CA2225255A1 CA002225255A CA2225255A CA2225255A1 CA 2225255 A1 CA2225255 A1 CA 2225255A1 CA 002225255 A CA002225255 A CA 002225255A CA 2225255 A CA2225255 A CA 2225255A CA 2225255 A1 CA2225255 A1 CA 2225255A1
Authority
CA
Canada
Prior art keywords
substituted
methyl
unsubstituted
amino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002225255A
Other languages
English (en)
Inventor
Susumu Nishimura
Charles T. Caskey
Mari Yonemoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD KK
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603091.1A external-priority patent/GB9603091D0/en
Application filed by Individual filed Critical Individual
Publication of CA2225255A1 publication Critical patent/CA2225255A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions comprenant des quantités d'au moins deux agents thérapeutiques choisis dans un groupe constitué d'un inhibiteur de farnésyl-protéine transférase, lequel constitue un inhibiteur efficace de l'enzyme du fait qu'il se trouve en concurrence par rapport au substrat protéique de l'enzyme, et d'un inhibiteur de farnésyl-protéine transférase, lequel constitue un inhibiteur efficace de l'enzyme du fait qu'il se trouve en concurrence par rapport au farnésylpyrophosphate. L'invention concerne également des procédés d'inhibition de farnésyl-protéine transférase et de traitement du cancer chez un mammifère, lesquels procédés consistent à administrer audit mammifère, soit séquentiellement dans n'importe quel ordre soit simultanément, des doses d'au moins deux agents thérapeutiques choisis dans un groupe constitué d'un inhibiteur de farnésyl-protéine transférase, lequel constitue un inhibiteur efficace de l'enzyme du fait qu'il est un inhibiteur concurrentiel par rapport au substrat protéique de l'enzyme, et d'un inhibiteur de farnésyl-protéine transférase, lequel constitue un inhibiteur efficace de l'enzyme du fait qu'il est un inhibiteur concurrentiel par rapport au farnésyle pyrophosphate en des doses suffisantes pour obtenir un effet thérapeutique ou synergique. L'invention concerne en outre des procédés de préparation de ces compositions.
CA002225255A 1995-06-29 1996-06-26 Combinaisons d'inhibiteurs de farnesyl-proteine transferase Abandoned CA2225255A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US225195P 1995-06-29 1995-06-29
US60/002,251 1995-06-29
GBGB9603091.1A GB9603091D0 (en) 1996-02-14 1996-02-14 Combinations of inhibitors of farnesyl-protein transferase
GB9603091.1 1996-02-14

Publications (1)

Publication Number Publication Date
CA2225255A1 true CA2225255A1 (fr) 1997-01-16

Family

ID=26308700

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002225255A Abandoned CA2225255A1 (fr) 1995-06-29 1996-06-26 Combinaisons d'inhibiteurs de farnesyl-proteine transferase

Country Status (5)

Country Link
EP (1) EP0836383A1 (fr)
JP (1) JP2000501063A (fr)
AU (1) AU714072B2 (fr)
CA (1) CA2225255A1 (fr)
WO (1) WO1997001275A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0805154A1 (fr) * 1994-08-12 1997-11-05 Banyu Pharmaceutical Co., Ltd. Derive d'acide amique n,n-bisubstitue
DE69635114T2 (de) * 1995-08-09 2006-03-02 Banyu Pharmaceutical Co., Ltd. Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
AU1619497A (en) * 1996-02-07 1997-08-28 Banyu Pharmaceutical Co., Ltd. Substituted amide derivatives
DE69714303T2 (de) * 1996-02-07 2003-01-23 Banyu Pharma Co Ltd N,n-disubstituierte carbonsaureamid-derivate
CA2244695C (fr) * 1996-02-07 2006-01-03 Banyu Pharmaceutical Co., Ltd. Derives d'acides d'amides cycliques
ATE221045T1 (de) * 1996-02-07 2002-08-15 Banyu Pharma Co Ltd Substituierte amid-derivate
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
EP1002793B1 (fr) 1997-06-09 2003-09-24 Takara Bio Inc. Substances physiologiquement actives tkr2449, leur procede de preparation et micro-organisme
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US20030125326A1 (en) * 2000-02-29 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations
ES2576643T3 (es) 2007-03-09 2016-07-08 Second Genome, Inc. Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos
WO2008143947A1 (fr) * 2007-05-14 2008-11-27 University Of South Florida Dérivés de farnésylamine et procédés d'utilisation
JP6463366B2 (ja) 2013-10-10 2019-01-30 イースタン バージニア メディカル スクール １２−リポキシゲナーゼ阻害物質としての４−（（２−ヒドロキシ−３−メトキシベンジル）アミノ）ベンゼンスルホンアミド誘導体
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
JP7305658B2 (ja) 2018-01-31 2023-07-10 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗ｒｓｖ活性を有するシクロアルキル置換ピラゾロピリミジン
WO2019206828A1 (fr) 2018-04-23 2019-10-31 Janssen Sciences Ireland Unlimited Company Composés hétéroaromatiques ayant une activité contre vrs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298655A (en) * 1991-09-27 1994-03-29 Merck & Co., Inc. Farnesyl pyrophosphate analogs
US5340828A (en) * 1991-09-30 1994-08-23 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5245061A (en) * 1991-12-16 1993-09-14 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
EP0703905A1 (fr) * 1993-06-18 1996-04-03 Merck & Co. Inc. Inhibiteurs de farnesyle-proteine transferase
AU3192395A (en) * 1994-08-11 1996-03-07 Banyu Pharmaceutical Co., Ltd. Substituted amide derivative

Also Published As

Publication number Publication date
AU714072B2 (en) 1999-12-16
EP0836383A1 (fr) 1998-04-22
JP2000501063A (ja) 2000-02-02
AU6399696A (en) 1997-01-30
WO1997001275A1 (fr) 1997-01-16

Similar Documents

Publication Publication Date Title
CA2225255A1 (fr) Combinaisons d'inhibiteurs de farnesyl-proteine transferase
US5840918A (en) Isoprenyl transferase inhibitors
WO1997038664A2 (fr) Methode de traitement de cancer
AU714687B2 (en) Thiol sulfone metalloprotease inhibitors
US6989383B1 (en) Method of treating cancer
WO1995029892A1 (fr) Derives d'acides hydroxamiques et d'acides amines et leur utilisation comme agents antiarthritiques
KR100400507B1 (ko) 치환 피롤리딘 히드록사메이트 메탈로프로테아제 억제제
CA2216707A1 (fr) Inhibiteurs de farnesyl-proteine transferase
JPH11504015A (ja) メタロプロテアーゼおよびｔｎｆ阻害剤としての新規なヒドロキサム酸およびアミノ−カルボキシレート化合物
JP2000504023A (ja) 癌治療方法
PH26082A (en) Amino acid derivatives
BG102936A (bg) Инхибитори на протеин фарнезил трансфераза
BG105788A (bg) Сулфамато хидроксамова киселина като металопротеазен инхибитор
EP0307837A2 (fr) Peptidylhétérocycles inhibant la rénine
JPH11504320A (ja) メタロプロテアーゼ阻害剤としてのヒドロキサム酸およびカルボン酸
JP3647914B2 (ja) 環式アミノ酸誘導体
JPH03101648A (ja) ペプチジルアミノジオール系レニン抑制剤
JPH02290836A (ja) アミノ酸誘導体
SK16742000A3 (sk) Kombinácie proteínovej farnesyltransferázy a inhibítorov hmg coa reduktázy a ich použitie pri liečbe rakoviny
AU4701799A (en) Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions
AU724331B2 (en) Compounds useful in the treatment of neurofibromatosis
TW201418198A (zh) 轉麩醯胺酸酶ｔｇ２抑制劑，醫藥組成物及其使用方法
JP2001509790A (ja) 金属タンパク質分解酵素阻害剤
JP2001506265A (ja) タンパク質ファルネシルトランスフェラーゼのシクロアルキル阻害剤
JP2001192398A (ja) セリンプロテアーゼ阻害剤

Legal Events

Date Code Title Description
FZDE Dead